Ligand validation:4CQY

NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose

NAG is a Ligand Of Interest in 4CQY designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
4CQY_NAG_A_1323	75%	56%	0.101	0.934	0.47	1.19	-	2	0	0	100%	0.9333
4CQY_NAG_E_1323	63%	58%	0.136	0.931	0.5	1.09	-	2	0	0	100%	0.9333
4CQY_NAG_C_1323	50%	62%	0.173	0.922	0.41	1.04	-	1	0	0	100%	0.9333
4CQY_NAG_E_1321	37%	54%	0.184	0.883	0.52	1.23	-	2	0	0	100%	0.9333
4CQY_NAG_A_1325	36%	57%	0.203	0.894	0.44	1.18	-	1	0	0	100%	0.9333
4CQY_NAG_A_1324	22%	48%	0.228	0.846	0.6	1.39	-	3	0	1	100%	0.9333
4CQY_NAG_C_1321	22%	55%	0.235	0.85	0.45	1.27	-	2	0	0	100%	0.9333
4CQY_NAG_C_1322	12%	53%	0.253	0.783	0.44	1.37	-	2	0	0	100%	0.9333
4CQY_NAG_E_1322	11%	52%	0.283	0.806	0.57	1.25	-	3	1	1	100%	0.9333
4CQW_NAG_A_1011	80%	55%	0.117	0.966	0.45	1.25	-	1	0	0	100%	0.9333
4CQX_NAG_C_1322	80%	53%	0.093	0.94	0.51	1.29	-	2	0	0	100%	0.9333
4CQV_NAG_C_1011	59%	62%	0.156	0.94	0.49	0.97	-	2	0	0	100%	0.9333
5E2Z_NAG_C_1001	39%	80%	0.176	0.882	0.38	0.47	-	-	0	0	100%	0.9333
4KW1_NAG_E_405	17%	33%	0.134	0.706	0.94	1.67	-	2	0	1	100%	0.9333
3H0C_NAG_A_794	100%	56%	0.021	0.995	0.61	1.08	-	1	0	0	100%	0.9333
5LDS_NAG_B_1007	100%	67%	0.022	0.995	0.48	0.79	-	-	0	0	100%	0.9333
5O5D_NAG_A_601	100%	65%	0.022	0.994	0.32	0.99	-	1	0	0	100%	0.9333
6MUG_NAG_G_629	100%	76%	0.022	0.994	0.35	0.58	-	-	0	0	100%	0.9333
3GXM_NAG_A_498	100%	45%	0.026	0.992	0.75	1.34	-	2	0	0	100%	0.9333

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.